Neurodegenerative disease management最新文献_第6页

Reviving mitochondria to restore the mind: stem cell-based bioenergetic rescue in Parkinson's disease. 恢复线粒体以恢复心智：基于干细胞的帕金森氏症生物能量救援。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2025-09-19 DOI: 10.1080/17582024.2025.2562741

Supriya Shidhaye, Anis Ahmad Chaudhary, Mayuri Gajghate, Priyanka Singanwad, Milind Umekar, Neha Raut, Hassan Ahmad Rudayni, Rashmi Trivedi

{"title":"Reviving mitochondria to restore the mind: stem cell-based bioenergetic rescue in Parkinson's disease.","authors":"Supriya Shidhaye, Anis Ahmad Chaudhary, Mayuri Gajghate, Priyanka Singanwad, Milind Umekar, Neha Raut, Hassan Ahmad Rudayni, Rashmi Trivedi","doi":"10.1080/17582024.2025.2562741","DOIUrl":"10.1080/17582024.2025.2562741","url":null,"abstract":"Parkinson's disease is a neurodegenerative disorder of aging with dopaminergic neuronal degeneration in the substantia nigra leading to motor dysfunction. Mitochondrial dysfunction is central to its pathophysiology, leading to oxidative stress, derangement of energy metabolism, and induction of neuronal apoptosis. Current therapeutic interventions are symptomatic but fail to stop disease progression. Stem cell-based regenerative strategies have been recognized as potential disease-modifying treatments. Mitochondria-augmented stem cell therapy offers a new mechanism for the correction of cellular bioenergetic deficits. Through genetic manipulations or preconditioning protocols, mesenchymal stem cells and induced pluripotent stem cells are engineered to enhance mitochondrial function and transfer. The engineered cells enable delivery of functional mitochondria into damaged neurons through tunneling nanotubes or extracellular vesicles, promoting ATP production, inhibiting reactive oxygen species, and restoring mitophagy. Preclinical models have demonstrated improved neuronal survival and motor function, and novel technologies like CRISPR gene editing and 3D bioprinting offer improved translational relevance.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"473-483"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study. 非典型帕金森病与自身免疫相关的免疫系统改变-一项病例对照研究。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-08-01 Epub Date: 2025-10-14 DOI: 10.1080/17582024.2025.2573597

Annamma Mathai, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Meena Thevarkalam, Anandkumar Anandakuttan, Sugavanan Kalingavarman, Ullas Mony, Manu Raj, Renjitha Bhaskaran

{"title":"Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study.","authors":"Annamma Mathai, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Meena Thevarkalam, Anandkumar Anandakuttan, Sugavanan Kalingavarman, Ullas Mony, Manu Raj, Renjitha Bhaskaran","doi":"10.1080/17582024.2025.2573597","DOIUrl":"10.1080/17582024.2025.2573597","url":null,"abstract":"Background: Inflammation is known in atypical parkinsonism (AP), but the role of autoimmunity is unclear. This study evaluates immune system modifications suggesting autoimmunity in AP.Methods: Included patients with AP diagnosed at Amrita Institute of Medical Sciences, Kochi (December 2018-May 2019), and age- and sex-matched controls. Fifteen immune parameters, including T regulatory cells, RORγt, and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, IL-21, IL-22, IL-23, TNF, IFN-γ, GM-CSF, NF-κB, TGF-β), were assessed in peripheral blood (flow cytometry and ELISA).Results: Twenty-six cases (mean age 67.8 ± 7.5 years; 16 males) and 15 controls (mean age 68.1 ± 3.5 years; 10 males) studied. Diagnoses included progressive supranuclear palsy (n = 15), multiple system atrophy (n = 1), frontotemporal dementia with parkinsonism (n = 2), and unspecified AP (n = 8). AP cases had significantly higher RORγt (p = 0.041), IL-6 (p = 0.004), TNF (p = 0.020), IL-10 (p = 0.027), and IL-4 (p = 0.048).Conclusions: Elevated RORγt and cytokines suggest immune dysregulation and possible autoimmune mechanisms in AP, warranting further investigation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"411-416"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reproductive health in multiple sclerosis patients: overcoming challenges and improving patient care. 多发性硬化症患者的生殖健康：克服挑战和改善患者护理。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-07-31 DOI: 10.1080/17582024.2026.2710759

Sarah MacIsaac, Kristen M Krysko

引用次数: 0

Dietary total antioxidant capacity, diet quality and quality of life in adults with and without dementia. 饮食总抗氧化能力，饮食质量和生活质量的成年人有和没有痴呆。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-07-26 DOI: 10.1080/17582024.2026.2708791

Azime İrem Kuruhalil, Berkin Özyılmaz Kırcali

{"title":"Dietary total antioxidant capacity, diet quality and quality of life in adults with and without dementia.","authors":"Azime İrem Kuruhalil, Berkin Özyılmaz Kırcali","doi":"10.1080/17582024.2026.2708791","DOIUrl":"10.1080/17582024.2026.2708791","url":null,"abstract":"Aims: This study aimed to evaluate dietary total antioxidant capacity (DTAC), diet quality, nutrient intake, and quality of life in adults aged 45 years and older with and without dementia.Materials and methods: In this cross-sectional study, 102 adults, including 51 individuals with dementia and 51 cognitively healthy controls, were assessed. Dietary intake was evaluated using a food frequency questionnaire. DTAC was calculated using ferric reducing antioxidant power (FRAP) values. Diet quality was assessed using the Healthy Eating Index-2020 (HEI-2020), and quality of life was measured using the Short Form-12 (SF-12).Results: Individuals with dementia had lower DTAC, lower intake of many macro- and micronutrients, and lower physical and mental quality-of-life scores than controls. HEI-2020 component scores differed significantly only for total fruit and whole fruit intake. No significant association was observed between DTAC and quality-of-life scores in either group.Conclusion: Nutritional inadequacy and lower quality of life were evident among adults with dementia. Comprehensive nutritional assessment and support may be important components of dementia care.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":2.8,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the microbiota-gut-brain axis in neurodegeneration: Zebrafish-based investigations. 在神经退行性疾病中靶向微生物-肠-脑轴：基于斑马鱼的研究。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-07-25 DOI: 10.1080/17582024.2026.2705869

Bharti Verma, Rahul Kumar, Avani Sharma, Nitish Kumar, Zuber Khan, Sumel Ashique, Ranjna Rani, Vedpal Singh Parihar, Sonakshi Antal, Mumtaz, Alok Anand

{"title":"Targeting the microbiota-gut-brain axis in neurodegeneration: Zebrafish-based investigations.","authors":"Bharti Verma, Rahul Kumar, Avani Sharma, Nitish Kumar, Zuber Khan, Sumel Ashique, Ranjna Rani, Vedpal Singh Parihar, Sonakshi Antal, Mumtaz, Alok Anand","doi":"10.1080/17582024.2026.2705869","DOIUrl":"https://doi.org/10.1080/17582024.2026.2705869","url":null,"abstract":"The microbiota-gut-brain axis (MGBA) is a bidirectional signaling pathway regulated by the gut microbiome and the central nervous system (CNS). Moreover, MGBA is crucial for normal growth, development, and physiology of the brain and gut of the host; dysfunction in MGBA has been closely linked with the development of neurological disorders. Gut dysbiosis and its metabolites modulate barrier permeability and cause gastrointestinal tract (GIT) inflammation, which is followed by an increase in pro-inflammatory cytokines, immune cell infiltration into the brain, and vagus nerve dysfunction, resulting in neuroinflammation and neuronal defects in the brain, as well as some other behavioral defects. In this review, we will discuss the molecular and neurobehavioral properties of Zebrafish as a research model to study MGBA, as well as current discoveries in humans, highlighting the vital role of MGBA in neuropathological conditions. Using Zebrafish as a genetic model in combination with in vivo imaging technology may suggest some novel mechanisms for the interaction between gut microbiota and CNS, particularly in the case of neurological disorders including Alzheimer's disease (AD), Parkinson's disease (PD) and autism spectrum disorder (ASD). A comprehensive literature search was conducted using electronic databases including PubMed, Scopus, Web of Science, and Google Scholar.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supporting gastrostomy decision-making in motor neurone disease (MND): an Australian survey of healthcare professionals' beliefs, practices, and needs. 支持运动神经元疾病（MND）的胃造口术决策：澳大利亚对医疗保健专业人员的信念、实践和需求的调查。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-06-12 DOI: 10.1080/17582024.2026.2687483

Sarah El-Wahsh, Elise Bogart, Susannah Bonnor, Shadi El-Wahsh, Marnie Graco, Anne Hogden, Camille Paynter, Veena Raykar, Monique Signorelli, Emma Thomson, Steve Vucic, Sean White

{"title":"Supporting gastrostomy decision-making in motor neurone disease (MND): an Australian survey of healthcare professionals' beliefs, practices, and needs.","authors":"Sarah El-Wahsh, Elise Bogart, Susannah Bonnor, Shadi El-Wahsh, Marnie Graco, Anne Hogden, Camille Paynter, Veena Raykar, Monique Signorelli, Emma Thomson, Steve Vucic, Sean White","doi":"10.1080/17582024.2026.2687483","DOIUrl":"https://doi.org/10.1080/17582024.2026.2687483","url":null,"abstract":"Introduction: Gastrostomy decision-making for people living with motor neurone disease (MND) is complex. While international studies report healthcare professionals' (HCPs) beliefs and practices in this area, little is known about the Australian context.Aim: To examine Australian HCPs' beliefs, clinical practices, and support needs regarding gastrostomy decision-making in MND.Methods: A national cross-sectional online survey of Australian HCPs involved in gastrostomy discussions (n = 123) was conducted, exploring five domains: 1) initiating discussions and timing; 2) patient education; 3) multidisciplinary coordination; 4) guideline use; 5) and professional development needs. Descriptive statistics were applied.Results: Most HCPs initiated discussions about gastrostomy (74%), commonly prompted by swallowing difficulty, weight loss, or patient request. Although 72% believed discussions should occur before clinical indications, only 40% reported doing so. Earlier placement was favored in the context of respiratory decline compared with swallowing impairment, and 56% considered gastrostomy to be performed too late. Almost 40% used no formal guidelines, and 74% wanted further professional development.Conclusion: Australian HCPs valued person-centered practice, but belief-practice gaps highlight opportunities to improve consistency, timing, and quality of gastrostomy decision-making support. Enhanced national guidelines, improved multidisciplinary communication, and targeted professional development may help reduce delays and better align practice with evidence-based recommendations.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-17"},"PeriodicalIF":3.4,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148227090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between influenza infection and subsequent Parkinson's disease diagnosis: a systematic review and meta-analysis. 流感感染与随后帕金森病诊断之间的关系：一项系统综述和荟萃分析。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-06-12 DOI: 10.1080/17582024.2026.2687479

Alice Halim, Shin Jie Yong, Anood A Alenezy, Maha A Aljumaa, Zainab H Almansour, Hayam A Alrasheed, Ali Hazazi, Nawal A Al Kaabi, Ali A Zaidan, Mashahed Y Almoutawa, Nada N Alshehri, Jumana M Al-Jishi, Mohammed S Almogbel, Rana Abdulrahim Ali Alaeq, Ali A Rabaan

{"title":"Association between influenza infection and subsequent Parkinson's disease diagnosis: a systematic review and meta-analysis.","authors":"Alice Halim, Shin Jie Yong, Anood A Alenezy, Maha A Aljumaa, Zainab H Almansour, Hayam A Alrasheed, Ali Hazazi, Nawal A Al Kaabi, Ali A Zaidan, Mashahed Y Almoutawa, Nada N Alshehri, Jumana M Al-Jishi, Mohammed S Almogbel, Rana Abdulrahim Ali Alaeq, Ali A Rabaan","doi":"10.1080/17582024.2026.2687479","DOIUrl":"https://doi.org/10.1080/17582024.2026.2687479","url":null,"abstract":"Introduction: As infectious agents may be associated with neurodegenerative diseases, this systematic review and meta-analysis investigated whether prior influenza infection is associated with an increased odds of subsequent Parkinson's disease (PD) diagnosis.Methods: We searched PubMed, Web of Science, and Scopus for observational studies examining influenza infection and later PD diagnosis. Seven studies (comprising eight cohorts) were analyzed using frequentist and Bayesian random-effects meta-analyses. Meta-regression and subgroup analyses were conducted to explore the moderating effect of the time interval between influenza exposure and subsequent PD diagnosis (i.e. exposure window).Results: A significant association was observed in both approaches: pooled OR = 1.87 (95% CI: 1.24-2.81) under the frequentist model, and posterior median OR = 1.88 (95% CrI: 1.07-3.36) under the Bayesian model. Meta-regression and subgroup analyses identified the influenza exposure window as a moderator (R2 = 36.6%, p < 0.05), with studies reporting influenza exposure within five years before PD diagnosis showing the strongest associations.Conclusion: Our findings support a probable and temporally sensitive association between influenza infection and subsequent PD diagnosis. However, these findings should be interpreted cautiously, given the retrospective and heterogeneous nature of the available data.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148227083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bright light therapy for depression and excessive daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression. 强光疗法治疗帕金森病患者的抑郁和日间嗜睡：剂量-反应meta回归随机对照试验的系统回顾和meta分析

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-30 DOI: 10.1080/17582024.2026.2681564

Mark Messak, Ahmed Abdelmageed, Youssef A Khattab, Youssef Mandour, Omar Shaker, Ahmed Negida

{"title":"Bright light therapy for depression and excessive daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression.","authors":"Mark Messak, Ahmed Abdelmageed, Youssef A Khattab, Youssef Mandour, Omar Shaker, Ahmed Negida","doi":"10.1080/17582024.2026.2681564","DOIUrl":"https://doi.org/10.1080/17582024.2026.2681564","url":null,"abstract":"Background: Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD.Methods: PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed.Results: Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent.Conclusion: BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-16"},"PeriodicalIF":3.4,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding the phenotypic spectrum of SOD1‑related ALS: upper motor neuron predominance in a p.D91A case. 扩大SOD1相关ALS的表型谱：p.D91A病例的上运动神经元优势

IF 3.4

Neurodegenerative disease management Pub Date : 2026-05-25 DOI: 10.1080/17582024.2026.2676822

Laura Tavaglione, Niccolò Madonia, Lucia Corrado, Cristoforo Comi, Sandra D'Alfonso, Letizia Mazzini, Fabiola De Marchi

引用次数: 0

Letter to the editor regarding "Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice". 致编辑关于“临床实践中ofatumumab的真实世界有效性、持久性、耐受性和安全性”的信。

IF 2.8

Neurodegenerative disease management Pub Date : 2026-05-24 DOI: 10.1080/17582024.2026.2677453

Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo

引用次数: 0